Literature DB >> 20050839

An integrated model for the glucose-insulin system.

Hanna E Silber1, Petra M Jauslin, Nicolas Frey, Mats O Karlsson.   

Abstract

The integrated glucose-insulin model was originally developed on a variety of intravenous glucose provocation experiments in healthy volunteers and type 2 diabetic patients. The model, which simultaneously describes time-courses of glucose and insulin based on mechanism-based components for production, elimination and homeostatic feedback, has been further extended to oral glucose provocations, meal tests and insulin administration. The model has been used to describe experiments ranging from 4 to 24 hr. Applications of the integrated glucose-insulin model include the clinical assessment of the mechanism of action of anti-diabetic drugs and the magnitude of their effects. Finally, the model was used for optimizing the design of provocation experiments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20050839     DOI: 10.1111/j.1742-7843.2009.00510.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  13 in total

1.  Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.

Authors:  Cornelia B Landersdorfer; Yan-Ling He; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

2.  Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model.

Authors:  Karen B Schneck; Xin Zhang; Robert Bauer; Mats O Karlsson; Vikram P Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

3.  Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.

Authors:  Xin Zhang; Karen Schneck; Juliana Bue-Valleskey; Kwee Poo Yeo; Michael Heathman; Vikram Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

Review 4.  Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes.

Authors:  Elin Nyman; Yvonne J W Rozendaal; Gabriel Helmlinger; Bengt Hamrén; Maria C Kjellsson; Peter Strålfors; Natal A W van Riel; Peter Gennemark; Gunnar Cedersund
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906

5.  Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.

Authors:  Wei Gao; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2010-12-14       Impact factor: 4.030

Review 6.  Pharmacodynamic Drug-Drug Interactions.

Authors:  Jin Niu; Robert M Straubinger; Donald E Mager
Journal:  Clin Pharmacol Ther       Date:  2019-04-26       Impact factor: 6.875

7.  Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.

Authors:  Steve Choy; Emilie Hénin; Jan-Stefan van der Walt; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-24       Impact factor: 2.745

8.  Quantifying the contribution of the liver to glucose homeostasis: a detailed kinetic model of human hepatic glucose metabolism.

Authors:  Matthias König; Sascha Bulik; Hermann-Georg Holzhütter
Journal:  PLoS Comput Biol       Date:  2012-06-21       Impact factor: 4.475

9.  A Novel Insulin/Glucose Model after a Mixed-Meal Test in Patients with Type 1 Diabetes on Insulin Pump Therapy.

Authors:  Luca Marchetti; Federico Reali; Marco Dauriz; Corinna Brangani; Linda Boselli; Giulia Ceradini; Enzo Bonora; Riccardo C Bonadonna; Corrado Priami
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

10.  An Updated Organ-Based Multi-Level Model for Glucose Homeostasis: Organ Distributions, Timing, and Impact of Blood Flow.

Authors:  Tilda Herrgårdh; Hao Li; Elin Nyman; Gunnar Cedersund
Journal:  Front Physiol       Date:  2021-06-01       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.